Natalizumab is a specific humanised monoclonal antibody, which inhibits
These affect the migration of leucocytes from the circulation
into the tissues to set up inflammatory reactions.
A multi-centre trial
of its effectiveness in severe Crohn’s disease was performed. After
2 infusions 71% of patients showed a response and 44% achieved clinical
remission at 6 weeks. Inflammatory protein levels in the blood improved.
The long term effectiveness is as yet unknown and this remains an experimental
treatment, which is not as yet generally available.
Further reading:NEJM 348 2003 24-32